Exhibit 99.1 Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress - On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024 - Demonstrated the versatility of Korro’s RNA editing platform by generating de-novo protein variants via multiple targets in non-human primates (NHPs) - Demonstrated greater than 50% editing using GalNAc conjugates in the liver with subcutaneous administration ...